Methods and systems for treating pregnancy-related hypertensive disorders comprising anti-sEng and anti-sFlt-1 antibodies

A method of treating a pregnancy-related hypertensive disorder in a subject in need thereof, the method comprising providing ex vivo to the subject an anti-soluble Endoglin (sEng) antibody or sEng-binding fragment thereof and an anti-soluble fms-like tyrosine kinase 1 (sFlt-1) antibody or sFlt-1-binding fragment thereof,

• wherein the anti-sEng antibody or sEng-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein each of the heavy chain and the light chain variable regions comprises a CDR1, CDR2, and CDR3, and wherein:
• the sequence of CDR1H comprises SEQ ID NO:7;
• the sequence of CDR2H comprises SEQ ID NO:8;
• the sequence of CDR3H comprises SEQ ID NO:9;
• the sequence of CDR1L comprises SEQ ID NO:10;
• the sequence of CDR2L comprises SEQ ID NO:11;
• the sequence of CDR3L comprises SEQ ID NO:12;
• and
• wherein the anti-sFlt-1 antibody or sFlt-1-binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein each of the heavy chain and the light chain variable regions comprises a CDR1, CDR2, and CDR3, and wherein:
• the sequence of CDR1H comprises SEQ ID NO:1;
• the sequence of CDR2H comprises SEQ ID NO:2;
• the sequence of CDR3H comprises SEQ ID NO:3;
• the sequence of CDR1L comprises SEQ ID NO:4;
• the sequence of CDR2L comprises SEQ ID NO:5;
• and
• the sequence of CDR3L comprises SEQ ID NO:6.